Boutique Venture Partners

Delfina is a data-driven prenatal care platform that personalizes pregnancy care to improve safety for mothers and babies. It uses a data-powered approach to uncover insights in prenatal care and to optimize interventional workflows through machine learning models. The platform creates individualized pregnancy care plans based on patient risk assessed from multiple metrics and supports early intervention, helping providers deliver equitable, cost-effective care. By integrating data across clinical, demographic, and monitoring inputs, Delfina aims to enhance decision-making, streamline workflows, and improve outcomes throughout pregnancy.

Handl Health operates a SaaS-based healthcare price transparency platform that aggregates and contextualizes price transparency, insurance, and demographic data. The solution helps health plans comply with CMS price transparency regulations while digitizing how patients shop, book, and pay for healthcare, enabling users to compare costs and make informed purchasing decisions.

Surge is a biotechnology company dedicated to enhancing surgical outcomes for patients. It has developed an advanced immunological model known as Surge2surgery, which predicts postoperative infections. This innovative platform integrates a single-cell analysis of the immune system conducted prior to surgery with clinical data, utilizing a proprietary machine-learning algorithm. By examining millions of immune cells from a small blood sample, Surge's technology simulates surgical trauma in a controlled environment, allowing for improved predictions and potentially better patient care.

FluidAI is a medical technology company focused on post-operative care, combining artificial intelligence with in-body data to improve patient monitoring. The company develops a smart catheter system that enables proactive post-operative care by detecting complications at onset and delivering critical health data to healthcare providers ahead of time.

Smartlens is a clinical-stage medical technology company focused on treating and diagnosing Glaucoma, a leading cause of irreversible blindness worldwide. Its flagship product, miLens, is an innovative eye pressure monitoring contact lens designed to improve early diagnosis, personalized treatment, and disease monitoring. This non-invasive, convenient solution aims to reduce the prevalence of glaucoma-related blindness, lower treatment costs, and alleviate the burden on lives and economies.

Zeda, formerly known as PrinterPrezz and Vertex Manufacturing, is a technology solutions company based in Fremont, California. Established in 2017, Zeda specializes in advanced manufacturing technologies, particularly in the fields of additive manufacturing, nanotechnology, and precision manufacturing. The company develops and manufactures innovative medical devices, such as the GAIA™ Lumbar Interbody Fusion Device, and provides essential tools including 3D printing machines, manipulation software, and scanners. Zeda serves highly regulated industries, including medical, aerospace, space, and defense, with a mission to enhance lives through the integration of groundbreaking technologies and innovative ideas. Its commitment to fostering collaboration and incubating new concepts positions Zeda as a leader in its sector.

Zeda, formerly known as PrinterPrezz and Vertex Manufacturing, is a technology solutions company based in Fremont, California. Established in 2017, Zeda specializes in advanced manufacturing technologies, particularly in the fields of additive manufacturing, nanotechnology, and precision manufacturing. The company develops and manufactures innovative medical devices, such as the GAIA™ Lumbar Interbody Fusion Device, and provides essential tools including 3D printing machines, manipulation software, and scanners. Zeda serves highly regulated industries, including medical, aerospace, space, and defense, with a mission to enhance lives through the integration of groundbreaking technologies and innovative ideas. Its commitment to fostering collaboration and incubating new concepts positions Zeda as a leader in its sector.

Surge is a biotechnology company dedicated to enhancing surgical outcomes for patients. It has developed an advanced immunological model known as Surge2surgery, which predicts postoperative infections. This innovative platform integrates a single-cell analysis of the immune system conducted prior to surgery with clinical data, utilizing a proprietary machine-learning algorithm. By examining millions of immune cells from a small blood sample, Surge's technology simulates surgical trauma in a controlled environment, allowing for improved predictions and potentially better patient care.

Delfina is a data-driven prenatal care platform that personalizes pregnancy care to improve safety for mothers and babies. It uses a data-powered approach to uncover insights in prenatal care and to optimize interventional workflows through machine learning models. The platform creates individualized pregnancy care plans based on patient risk assessed from multiple metrics and supports early intervention, helping providers deliver equitable, cost-effective care. By integrating data across clinical, demographic, and monitoring inputs, Delfina aims to enhance decision-making, streamline workflows, and improve outcomes throughout pregnancy.

CuraFi is a healthcare delivery and management company that specializes in providing specialty infusion services for patients with complex medical conditions. The company has developed an integrated specialty pharmacy and care delivery payment platform aimed at enhancing affordability and access to specialty medications. By aligning physicians and payers, CuraFi's platform helps manage patient costs and reduce medication expenses, while offering predictable payment structures on a per member per month basis. This approach enables healthcare centers to deliver life-saving medications and improve continuity of care, ultimately leading to better patient outcomes and new revenue opportunities for independent providers.

FluidAI is a medical technology company focused on post-operative care, combining artificial intelligence with in-body data to improve patient monitoring. The company develops a smart catheter system that enables proactive post-operative care by detecting complications at onset and delivering critical health data to healthcare providers ahead of time.

Filtricine is a Santa Clara, California-based biotechnology company focused on cancer therapy through targeted nutrient depletion. The company develops approaches that remove nutrients critical to cancer cell growth, enabling exploitation of cancer-specific metabolic dependencies without traditional drug substances. Through a nutrient modulation platform, Filtricine aims to identify metabolic vulnerabilities in cancers and apply strategies to deprive tumor cells of essential nutrients, potentially slowing or stopping disease progression. Founded in 2017, Filtricine operates as a clinical-stage, venture-backed biotechnology company dedicated to developing therapies that spare normal cells while targeting cancer metabolism.

miRecule is a biotechnology company developing targeted RNA therapies for cancer and muscular dystrophy. It uses its proprietary DREAmiR platform to analyze genomic data from thousands of patients, identifying genetic abnormalities and creating tailored RNA therapeutics to directly address these issues.

DocBot, Inc. is an artificial intelligence technology company based in Irvine, California, specializing in gastrointestinal diseases. The company develops web-based applications for iOS and Android devices that serve as a clinical decision support system, aggregating patient information and providing cloud analytics to healthcare professionals. Its flagship product is built on the UltivisionAI software platform, which offers real-time image analysis, automated reporting, and analytical tools aimed at enhancing patient care and clinical workflows. By integrating various data sources from imaging systems to pathology requisitions, DocBot's platform aids physicians in detecting colorectal cancer and other gastrointestinal conditions, ultimately striving to improve healthcare outcomes and reduce patient risks.

FluidAI is a medical technology company focused on post-operative care, combining artificial intelligence with in-body data to improve patient monitoring. The company develops a smart catheter system that enables proactive post-operative care by detecting complications at onset and delivering critical health data to healthcare providers ahead of time.

Mesentech Inc. is a regenerative medicine company based in Vancouver, Canada, focused on developing innovative therapies for bone-related diseases. Established in 2013, the company specializes in a prodrug platform that delivers therapeutics selectively to bone, addressing challenges associated with conventional drug delivery methods. Mesentech's lead product, MES1007, is a bone-targeted prodrug of a prostaglandin mimetic that aims to reverse bone loss associated with conditions such as osteoporosis and Duchenne muscular dystrophy. The company's proprietary technology enhances the delivery of small-molecule and biological drugs to the bone's surface and interior, allowing for more effective treatment while minimizing side effects. This approach is particularly significant given the inherent difficulty in accessing bone tissue due to its hard surface and low porosity. Mesentech's focus on selective drug delivery not only aims to improve treatment efficacy but also hopes to accelerate bone healing and address complications associated with low bone density disorders.

Zeda, formerly known as PrinterPrezz and Vertex Manufacturing, is a technology solutions company based in Fremont, California. Established in 2017, Zeda specializes in advanced manufacturing technologies, particularly in the fields of additive manufacturing, nanotechnology, and precision manufacturing. The company develops and manufactures innovative medical devices, such as the GAIA™ Lumbar Interbody Fusion Device, and provides essential tools including 3D printing machines, manipulation software, and scanners. Zeda serves highly regulated industries, including medical, aerospace, space, and defense, with a mission to enhance lives through the integration of groundbreaking technologies and innovative ideas. Its commitment to fostering collaboration and incubating new concepts positions Zeda as a leader in its sector.

DocBot, Inc. is an artificial intelligence technology company based in Irvine, California, specializing in gastrointestinal diseases. The company develops web-based applications for iOS and Android devices that serve as a clinical decision support system, aggregating patient information and providing cloud analytics to healthcare professionals. Its flagship product is built on the UltivisionAI software platform, which offers real-time image analysis, automated reporting, and analytical tools aimed at enhancing patient care and clinical workflows. By integrating various data sources from imaging systems to pathology requisitions, DocBot's platform aids physicians in detecting colorectal cancer and other gastrointestinal conditions, ultimately striving to improve healthcare outcomes and reduce patient risks.

miRecule is a biotechnology company developing targeted RNA therapies for cancer and muscular dystrophy. It uses its proprietary DREAmiR platform to analyze genomic data from thousands of patients, identifying genetic abnormalities and creating tailored RNA therapeutics to directly address these issues.

QMENTA is a software company specializing in medical imaging management. They offer cloud-based solutions for clinical trials, neuroimaging disease packages, and neuro-data services, enabling efficient collection, processing, and analysis of large-scale brain images.

Smartlens is a clinical-stage medical technology company focused on treating and diagnosing Glaucoma, a leading cause of irreversible blindness worldwide. Its flagship product, miLens, is an innovative eye pressure monitoring contact lens designed to improve early diagnosis, personalized treatment, and disease monitoring. This non-invasive, convenient solution aims to reduce the prevalence of glaucoma-related blindness, lower treatment costs, and alleviate the burden on lives and economies.

Zeda, formerly known as PrinterPrezz and Vertex Manufacturing, is a technology solutions company based in Fremont, California. Established in 2017, Zeda specializes in advanced manufacturing technologies, particularly in the fields of additive manufacturing, nanotechnology, and precision manufacturing. The company develops and manufactures innovative medical devices, such as the GAIA™ Lumbar Interbody Fusion Device, and provides essential tools including 3D printing machines, manipulation software, and scanners. Zeda serves highly regulated industries, including medical, aerospace, space, and defense, with a mission to enhance lives through the integration of groundbreaking technologies and innovative ideas. Its commitment to fostering collaboration and incubating new concepts positions Zeda as a leader in its sector.

Frontier Bio Corporation is a biotechnology company based in Oakland, California, focused on developing and manufacturing advanced bioprinting technologies. Founded in 2018, the company specializes in creating lab-grown human tissues as an ethical alternative to animal studies. Its flagship product, the FLUX-1, is a 3D bioprinter that integrates conventional bioprinting methods with electro-hydrodynamic printing capabilities. This device enables the bioprinting of complex tissues such as skin, cartilage, and bone, and allows for applications in drug toxicity testing, tissue implants, drug screening, disease modeling, and prosthetics. By providing a means to produce human tissues with complete cell survivability, Frontier Bio aims to enhance the healthcare industry's ability to replace animal testing and address the organ transplant waitlist.